Immtech's DB289 placed on hold

IMM fell $2.97 (51%) to $2.88 after FDA placed the company's pafuramidine (DB289) program on clinical hold. The decision was based on data from an ongoing South African safety study that IMM said showed "abnormal laboratory values" in volunteers treated with pafuramidine. IMM said none of the subjects required treatment for the abnormalities. ...